See more
TribeMD
10 out, 2025
Lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab, a PCSK9-inhibiting monoclonal antibody, has already been shown to significantly reduce the risk of major adverse cardiovascular events in patients with a history of myocardial infarction (MI), stroke, or symptomatic peripheral artery disease¹.Despite these robust results in secondary prevention, there was still a gap in evidence regarding the role of evolocumab in the primary prevention of cardiovascular events in hi
5min
Published in Frontiers in Endocrinology (2025), this case report details a rare but life-threatening complication: severe euglycemic diabetic ketoacidosis (euDKA) following the simultaneous initiation of semaglutide (GLP-1 receptor agonist) and dapagliflozin (SGLT-2 inhibitor) in a patient with newly diagnosed type 2 diabetes mellitus (T2DM).The 36-year-old male initially showed good glycemic control after sta
7min
8 out, 2025
A case report published in Frontiers in Endocrinology (October 2025) by Gandecka-Pempera et al. highlights a rare but severe complication of combined GLP-1 receptor agonist (GLP-1 RA) and SGLT-2 inhibitor (SGLT-2i) therapy — euglycemic diabetic ketoacidosis (euDKA) refractory to standard management.The case involved a 36-year-old man with newly diagnosed type 2 diabetes mellitus (T2DM), obesit
6min
Show more
